HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Van Schil, P. E. Articles by van den Bosch, J. M. Search for Related Content PubMed PubMed Citation Articles by Van Schil, P. E. Articles by van den Bosch, J. M.

The Journal of Thoracic and Cardiovascular Surgery, Vol 104, 1451-1455, Copyright © 1992 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association

ARTICLES

Second primary lung cancer after bronchial sleeve resection. Treatment and results in eleven patients

PE Van Schil, A Brutel de la Riviere, PJ Knaepen, HA van Swieten, JJ Defauw and JM van den Bosch
Department of Thoracic Surgery, Antoniushospital, Nieuwegein, The Netherlands.

During the years 1960 to 1989, 145 patients underwent sleeve lobectomy or sleeve resection of a main bronchus. Follow-up was complete except for one patient, who was no longer available for follow-up 4 years after operation. Eleven patients (7.6%) had a second primary cancer in the lung; 10 of these patients (90.9%) were men. Mean age at sleeve operation was 61.2 +/- 11.6 years. Mean interval between sleeve operation and development of second primary cancer was 53.8 months (range, 6 to 197 months). All second primary cancers occurred on the contralateral side. In five cases there was squamous cell carcinoma, in two there was adenocarcinoma, in one there was adenosquamous carcinoma, in two there was small cell carcinoma, and in one patient no definite histologic type could be established. Five patients had different histologic type from the initial, resected primary tumor. Seven patients (64%) were operated on: five underwent lobectomy and two underwent segmentectomy. In one patient the tumor was judged to be unresectable. Chemotherapy was given to the two patients with small cell carcinoma and radiotherapy was given to one patient with bone metastases. Follow-up was complete for these 11 patients. Data were calculated from detection of second primary cancer. There was one postoperative death from myocardial infarction. Eight other patients died during follow-up: five died of recurrent tumor or metastases, two died of acute cardiac failure, and one died of a perforated ulcer. The 1- and 4-year actuarial survivals were 41% and 30%, respectively. For the patients operated on, 1- and 4-year survivals were 57% and 43%, respectively. There were no survivors at 5 years. Sleeve resection is a valuable method of preserving functional lung tissue. It offers a chance of subsequent resection in patients who have second primary cancer, with acceptable results.

This article has been cited by other articles:

				O. Chataigner, E. Fadel, B. Yildizeli, A. Achir, S. Mussot, D. Fabre, O. Mercier, and P. G. Dartevelle Factors affecting early and long-term outcomes after completion pneumonectomy Eur J Cardiothorac Surg, May 1, 2008; 33(5): 837 - 843. [Abstract] [Full Text] [PDF]

				J. Rubins, M. Unger, and G. L. Colice Follow-up and Surveillance of the Lung Cancer Patient Following Curative Intent Therapy: ACCP Evidence-Based Clinical Practice Guideline (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 355S - 367S. [Abstract] [Full Text] [PDF]

				Y. T. Kim, C. H. Kang, S. W. Sung, and J. H. Kim Local Control of Disease Related to Lymph Node Involvement in Non-Small Cell Lung Cancer After Sleeve Lobectomy Compared With Pneumonectomy Ann. Thorac. Surg., April 1, 2005; 79(4): 1153 - 1161. [Abstract] [Full Text] [PDF]

				A. Terzi, A. Lonardoni, G. Falezza, G. Furlan, P. Scanagatta, F. Pasini, and F. Calabro Sleeve lobectomy for non-small cell lung cancer and carcinoids: results in 160 cases Eur J Cardiothorac Surg, May 1, 2002; 21(5): 888 - 893. [Abstract] [Full Text] [PDF]

				S. Sartori, L. Trevisani, I. Nielsen, D. Tassinari, I. Panzini, and V. Abbasciano Randomized Trial of Omeprazole or Ranitidine Versus Placebo in the Prevention of Chemotherapy-Induced Gastroduodenal Injury J. Clin. Oncol., February 1, 2000; 18(3): 463 - 463. [Abstract] [Full Text] [PDF]

				M. Okada, N. Tsubota, M. Yoshimura, Y. Miyamoto, H. Matsuoka, S. Satake, and H. Yamagishi EXTENDED SLEEVE LOBECTOMY FOR LUNG CANCER: THE AVOIDANCE OF PNEUMONECTOMY J. Thorac. Cardiovasc. Surg., October 1, 1999; 118(4): 710 - 714. [Abstract] [Full Text] [PDF]

				P. Icard, J. F. Regnard, L. Guibert, P. Magdeleinat, B. Jauffret, and P. Levasseur Survival and prognostic factors in patients undergoing parenchymal saving bronchoplastic operation for primary lung cancer: a series of 110 consecutive cases Eur J Cardiothorac Surg, April 1, 1999; 15(4): 426 - 432. [Abstract] [Full Text] [PDF]

				P. E. Van Schil, A. B. de la Riviere, P. J. Knaepen, H. A. van Swieten, S. W. Reher, D. J. Goossens, R. G. Vanderschueren, and J. M. van den Bosch Long-Term Survival After Bronchial Sleeve Resection: Univariate and Multivariate Analyses Ann. Thorac. Surg., April 1, 1996; 61(4): 1087 - 1091. [Abstract] [Full Text]

				R. J. Mehran, J. Deslauriers, M. Piraux, M. Beaulieu, C. Guimont, and J. Brisson Survival related to nodal status after sleeve resection for lung cancer J. Thorac. Cardiovasc. Surg., February 1, 1994; 107(2): 576 - 583. [Abstract] [Full Text]